Patents by Inventor Daqing Wang

Daqing Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20160312225
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: July 13, 2016
    Publication date: October 27, 2016
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9453228
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: September 27, 2016
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20160251652
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 1, 2016
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF
    Publication number: 20160237437
    Abstract: The invention provides antagonist of TLR9 and methods of use thereof. These compounds inhibit or suppress TLR9-mediated signaling. The methods may have use in the prevention and treatment of diseases or disorders mediated by TLR9.
    Type: Application
    Filed: February 11, 2016
    Publication date: August 18, 2016
    Inventors: Sudhir Agrawal, Daqing Wang, Fu-Gang Zhu
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20160215287
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: July 6, 2015
    Publication date: July 28, 2016
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20160201060
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 14, 2016
    Inventors: Ekambar Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20160138022
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: December 1, 2015
    Publication date: May 19, 2016
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS
    Publication number: 20160101128
    Abstract: The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.
    Type: Application
    Filed: October 9, 2015
    Publication date: April 14, 2016
    Inventors: Daqing Wang, Wayne Jiang, Sudhir Agrawal
  • WAVELENGTH BEAM COMBINING LASER SYSTEMS UTILIZING LENS ROLL FOR CHIEF RAY FOCUSING
    Publication number: 20160048028
    Abstract: In various embodiments, a wavelength beam combining laser system includes a fast-axis collimation lens that is rotated with respect to a plurality of emitters in order to converge the emitted beams onto a dispersive element and/or reduce the size of the multi-wavelength output beam of the system.
    Type: Application
    Filed: June 8, 2015
    Publication date: February 18, 2016
    Inventors: Michael Deutsch, Daqing Wang, James Zambuto, Bien Chann, Bryan Lochman
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9260719
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: February 16, 2016
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
    Patent number: 9243050
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: January 26, 2016
    Assignee: Idera Pharamaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Putta, Sudhir Agrawal
  • LENS MOUNTING ARRANGEMENTS FOR HIGH-POWER LASER SYSTEMS
    Publication number: 20150364901
    Abstract: In various embodiments, a laser apparatus includes top and bottom electrode mounts, a beam emitter between the electrode mounts, a fast axis collimation lens, an optical rotator, and a lens holder or lens mount positioning the lens and the optical rotator to intercept one or more beams emitted by the beam emitter.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 17, 2015
    Inventors: Michael Deutsch, Daqing Wang
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9206430
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: December 8, 2015
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9096858
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: August 4, 2015
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • Smile Correction using FAC Lens Deformation
    Publication number: 20150062891
    Abstract: A system and method of providing a deformed FAC Lens to a multi-emitter diode bar laser system comprised of a lens holder and FAC lens wherein the FAC Lens is deformed so as to offset or compensate for the inherent smile properties present in a multi-emitter diode bar.
    Type: Application
    Filed: September 3, 2014
    Publication date: March 5, 2015
    Applicant: TERADIODE, INC.
    Inventors: Michael Deutsch, Daqing Wang
  • STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8
    Publication number: 20140308300
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 16, 2014
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Putta, Sudhir Agrawal
  • Toll like receptor modulators
    Patent number: 8853375
    Abstract: The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: October 7, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Lakshmi Bhagat, Mallikarjuna Putta, Daqing Wang, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20140193396
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
    Patent number: 8759310
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: June 24, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20140004100
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: May 30, 2013
    Publication date: January 2, 2014
    Applicant: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal